Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

No Magic Pill: A Prescription for Enhanced Shared Decision-Making for Depression Treatment.

Cosgrove L, Erlich D, Shaughnessy AF.

J Am Board Fam Med. 2019 Jan-Feb;32(1):6-9. doi: 10.3122/jabfm.2019.01.180182.

2.

A Combined Free-Flow Electrophoresis and DIGE Approach to Compare Proteins in Complex Biological Samples.

Fung KYC, Cursaro C, Lewanowitsch T, Cosgrove L, Hoffmann P.

Methods Mol Biol. 2019;1855:403-415. doi: 10.1007/978-1-4939-8793-1_34.

PMID:
30426435
3.

Evidence-based practice: a comparison of International Clinical Practice Guidelines and current research on physical activity for mild to moderate depression.

Hess CW, Karter J, Cosgrove L, Hayden L.

Transl Behav Med. 2018 Oct 13. doi: 10.1093/tbm/iby092. [Epub ahead of print]

PMID:
30321410
4.

Variation in analytic transparency in recent efficacy studies of antidepressant medication.

Vannoy S, Brodt M, Cosgrove L, Shaughnessy AF.

BMJ Evid Based Med. 2018 Oct;23(5):177-182. doi: 10.1136/bmjebm-2018-110947. Epub 2018 Jun 27.

PMID:
29950314
5.

Unexamined assumptions and unintended consequences of routine screening for depression.

Cosgrove L, Karter JM, Vaswani A, Thombs BD.

J Psychosom Res. 2018 Jun;109:9-11. doi: 10.1016/j.jpsychores.2018.03.007. Epub 2018 Mar 18. No abstract available.

PMID:
29773154
6.

When is a guideline not a guideline? The devil is in the details.

Cosgrove L, Shaughnessy AF, Shaneyfelt T.

BMJ Evid Based Med. 2018 Feb;23(1):33-36. doi: 10.1136/ebmed-2017-110845. No abstract available.

PMID:
29367325
7.

Antipsychotic augmentation for major depressive disorder: A review of clinical practice guidelines.

Simons P, Cosgrove L, Shaughnessy AF, Bursztajn H.

Int J Law Psychiatry. 2017 Nov - Dec;55:64-71. doi: 10.1016/j.ijlp.2017.10.003. Epub 2017 Nov 8. Review.

PMID:
29157513
8.

Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma.

Head RJ, Fay MF, Cosgrove L, Y C Fung K, Rundle-Thiele D, Martin JH.

Cancer Biol Ther. 2017 Dec 2;18(12):917-926. doi: 10.1080/15384047.2017.1385680. Epub 2017 Nov 20. Review.

9.

Developing a Clinician Friendly Tool to Identify Useful Clinical Practice Guidelines: G-TRUST.

Shaughnessy AF, Vaswani A, Andrews BK, Erlich DR, D'Amico F, Lexchin J, Cosgrove L.

Ann Fam Med. 2017 Sep;15(5):413-418. doi: 10.1370/afm.2119.

11.

Conflicts of Interest and the Presence of Methodologists on Guideline Development Panels: A Cross-Sectional Study of Clinical Practice Guidelines for Major Depressive Disorder.

Cosgrove L, Shaughnessy AF, Peters SM, Lexchin JR, Bursztajn H, Bero L.

Psychother Psychosom. 2017;86(3):168-170. doi: 10.1159/000458727. Epub 2017 May 11. No abstract available.

PMID:
28490018
12.

The Need to Systematically Evaluate Clinical Practice Guidelines.

Shaughnessy AF, Cosgrove L, Lexchin JR.

J Am Board Fam Med. 2016 Nov 12;29(6):644-648. doi: 10.3122/jabfm.2016.06.160115.

13.

Conflict of Interest Policies and Industry Relationships of Guideline Development Group Members: A Cross-Sectional Study of Clinical Practice Guidelines for Depression.

Cosgrove L, Krimsky S, Wheeler EE, Peters SM, Brodt M, Shaughnessy AF.

Account Res. 2017;24(2):99-115. Epub 2016 Oct 24.

PMID:
27901595
14.

Valproate in Adjuvant Glioblastoma Treatment.

Fay MF, Head R, Sminia P, Dowson N, Cosgrove L, Rose SE, Martin JH.

J Clin Oncol. 2016 Sep 1;34(25):3105-7. doi: 10.1200/JCO.2016.67.2162. Epub 2016 Jun 13. No abstract available.

PMID:
27298401
15.

Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation.

Cosgrove L, Vannoy S, Mintzes B, Shaughnessy AF.

Account Res. 2016;23(5):257-79. doi: 10.1080/08989621.2016.1153971.

PMID:
26890488
16.
17.

Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.

Rundle-Thiele D, Head R, Cosgrove L, Martin JH.

Br J Clin Pharmacol. 2016 Feb;81(2):199-209. doi: 10.1111/bcp.12785. Epub 2015 Oct 30. Review.

18.

Corruption impairs discussion on long term use of psychiatric drugs.

Whitaker R, Cosgrove L.

BMJ. 2015 Jun 2;350:h2953. doi: 10.1136/bmj.h2953. No abstract available.

PMID:
26038250
19.

Blood-based protein biomarker panel for the detection of colorectal cancer.

Fung KY, Tabor B, Buckley MJ, Priebe IK, Purins L, Pompeia C, Brierley GV, Lockett T, Gibbs P, Tie J, McMurrick P, Moore J, Ruszkiewicz A, Nice E, Adams TE, Burgess A, Cosgrove LJ.

PLoS One. 2015 Mar 20;10(3):e0120425. doi: 10.1371/journal.pone.0120425. eCollection 2015.

20.

The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.

Hosein AN, Lim YC, Day B, Stringer B, Rose S, Head R, Cosgrove L, Sminia P, Fay M, Martin JH.

J Neurooncol. 2015 Apr;122(2):263-71. doi: 10.1007/s11060-014-1713-x. Epub 2015 Feb 4.

PMID:
25648357
21.

Program fidelity measures associated with an effective child restraint program: Buckle-Up Safely.

Hunter K, Keay L, Simpson JM, Brown J, Bilston LE, Fegan M, Cosgrove L, Stevenson M, Ivers RQ.

Am J Public Health. 2015 Mar;105(3):584-90. doi: 10.2105/AJPH.2014.302308. Epub 2015 Jan 20.

22.

Delineation of the IGF-II C domain elements involved in binding and activation of the IR-A, IR-B and IGF-IR.

Henderson ST, Brierley GV, Surinya KH, Priebe IK, Catcheside DE, Wallace JC, Forbes BE, Cosgrove LJ.

Growth Horm IGF Res. 2015 Feb;25(1):20-7. doi: 10.1016/j.ghir.2014.09.004. Epub 2014 Oct 30.

PMID:
25458127
23.

From caveat emptor to caveat venditor: time to stop the influence of money on practice guideline development.

Cosgrove L, Shaughnessy AF, Wheeler EE, Krimsky S, Peters SM, Freeman-Coppadge DJ, Lexchin JR.

J Eval Clin Pract. 2014 Dec;20(6):809-12. doi: 10.1111/jep.12244. Epub 2014 Oct 19. Review. No abstract available.

PMID:
25327453
24.

Claudin-1 Expression Is Elevated in Colorectal Cancer Precursor Lesions Harboring the BRAF V600E Mutation.

Caruso M, Fung KY, Moore J, Brierley GV, Cosgrove LJ, Thomas M, Cheetham G, Brook E, Fraser LM, Tin T, Tran H, Ruszkiewicz A.

Transl Oncol. 2014 Aug;7(4):456-63. doi: 10.1016/j.tranon.2014.05.009. Epub 2014 Jun 19.

25.

Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled.

Fung KY, Nice E, Priebe I, Belobrajdic D, Phatak A, Purins L, Tabor B, Pompeia C, Lockett T, Adams TE, Burgess A, Cosgrove L.

World J Gastroenterol. 2014 Jan 28;20(4):888-98. doi: 10.3748/wjg.v20.i4.888. Review.

26.

Tripartite conflicts of interest and high stakes patent extensions in the DSM-5.

Cosgrove L, Krimsky S, Wheeler EE, Kaitz J, Greenspan SB, DiPentima NL.

Psychother Psychosom. 2014;83(2):106-13. doi: 10.1159/000357499. Epub 2014 Jan 22.

27.

Drug firms, the codification of diagnostic categories, and bias in clinical guidelines.

Cosgrove L, Wheeler EE.

J Law Med Ethics. 2013 Fall;41(3):644-53. doi: 10.1111/jlme.12074.

PMID:
24088155
28.

Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer.

Fung KY, Priebe I, Purins L, Tabor B, Brierley GV, Lockett T, Nice E, Gibbs P, Tie J, McMurrick P, Moore J, Ruszkiewicz A, Burgess A, Cosgrove LJ.

Cancer Biomark. 2013;13(2):75-9. doi: 10.3233/CBM-130335.

PMID:
23838135
29.

Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in colorectal cancer patients.

Brierley GV, Priebe IK, Purins L, Fung KY, Tabor B, Lockett T, Nice E, Gibbs P, Tie J, McMurrick P, Moore J, Ruszkiewicz A, Burgess A, Cosgrove LJ.

Cancer Biomark. 2013;13(2):67-73. doi: 10.3233/CBM-130345.

PMID:
23838134
30.

Colorectal carcinogenesis: a cellular response to sustained risk environment.

Fung KY, Ooi CC, Zucker MH, Lockett T, Williams DB, Cosgrove LJ, Topping DL.

Int J Mol Sci. 2013 Jun 27;14(7):13525-41. doi: 10.3390/ijms140713525. Review.

31.

Conflicts of interest and the quality of recommendations in clinical guidelines.

Cosgrove L, Bursztajn HJ, Erlich DR, Wheeler EE, Shaughnessy AF.

J Eval Clin Pract. 2013 Aug;19(4):674-81. doi: 10.1111/jep.12016. Epub 2012 Dec 21.

PMID:
23731207
32.

Protecting the patient-physician relationship in Florida.

Schaechter J, Cosgrove LA, Rathore MH.

JAMA Pediatr. 2013 Apr;167(4):317-8. No abstract available.

PMID:
23675585
33.

Biochemical characterization of individual human glycosylated pro-insulin-like growth factor (IGF)-II and big-IGF-II isoforms associated with cancer.

Greenall SA, Bentley JD, Pearce LA, Scoble JA, Sparrow LG, Bartone NA, Xiao X, Baxter RC, Cosgrove LJ, Adams TE.

J Biol Chem. 2013 Jan 4;288(1):59-68. doi: 10.1074/jbc.M112.432013. Epub 2012 Nov 19.

34.

Identification of potential pathways involved in induction of apoptosis by butyrate and 4-benzoylbutyrate in HT29 colorectal cancer cells.

Fung KY, Ooi CC, Lewanowitsch T, Tan S, Tan HT, Lim TK, Lin Q, Williams DB, Lockett TJ, Cosgrove LJ, Chung MC, Head RJ.

J Proteome Res. 2012 Dec 7;11(12):6019-29. doi: 10.1021/pr3007107. Epub 2012 Nov 5.

PMID:
23057685
35.

Dynamic informed consent processes vital for treatment with antidepressants.

Gopal AA, Cosgrove L, Shuv-Ami I, Wheeler EE, Yerganian MJ, Bursztajn HJ.

Int J Law Psychiatry. 2012 Sep-Dec;35(5-6):392-7. doi: 10.1016/j.ijlp.2012.09.006. Epub 2012 Oct 2.

PMID:
23036363
36.

A review of the potential mechanisms for the lowering of colorectal oncogenesis by butyrate.

Fung KY, Cosgrove L, Lockett T, Head R, Topping DL.

Br J Nutr. 2012 Sep;108(5):820-31. doi: 10.1017/S0007114512001948. Epub 2012 Jun 7. Review.

PMID:
22676885
37.

A combined free flow electrophoresis and DIGE approach to compare proteins in complex biological samples.

Fung KY, Cursaro C, Lewanowitsch T, Cosgrove L, Hoffmann P.

Methods Mol Biol. 2012;869:135-46. doi: 10.1007/978-1-61779-821-4_12.

PMID:
22585483
38.

The American Psychiatric Association's guideline for major depressive disorder: a commentary.

Cosgrove L, Shaughnessy AF, Wheeler EE, Austad KE, Kirsch I, Bursztajn HJ.

Psychother Psychosom. 2012;81(3):186-8. doi: 10.1159/000335523. Epub 2012 Mar 17. No abstract available.

PMID:
22433532
39.

A comparison of DSM-IV and DSM-5 panel members' financial associations with industry: a pernicious problem persists.

Cosgrove L, Krimsky S.

PLoS Med. 2012;9(3):e1001190. doi: 10.1371/journal.pmed.1001190. Epub 2012 Mar 13. No abstract available.

40.

Nutrigenetics and nutrigenomics: viewpoints on the current status and applications in nutrition research and practice.

Fenech M, El-Sohemy A, Cahill L, Ferguson LR, French TA, Tai ES, Milner J, Koh WP, Xie L, Zucker M, Buckley M, Cosgrove L, Lockett T, Fung KY, Head R.

J Nutrigenet Nutrigenomics. 2011;4(2):69-89. doi: 10.1159/000327772. Epub 2011 May 28. Review.

41.

Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry.

Cosgrove L, Shi L, Creasey DE, Anaya-McKivergan M, Myers JA, Huybrechts KF.

PLoS One. 2011 Apr 6;6(4):e18210. doi: 10.1371/journal.pone.0018210. Review.

42.

Is the tissue persistence of O(6)-methyl-2'-deoxyguanosine an indicator of tumour formation in the gastrointestinal tract?

Tan SL, Gerber JP, Cosgrove LJ, Lockett TJ, Clarke JM, Williams DB, Head RJ.

Mutat Res. 2011 Apr 3;721(2):119-26. doi: 10.1016/j.mrgentox.2010.12.016. Epub 2011 Feb 2.

PMID:
21295156
43.

A combined free-flow electrophoresis and DIGE approach to identify proteins regulated by butyrate in HT29 cells.

Fung KY, Cursaro C, Lewanowitsch T, Brierley GV, McColl SR, Lockett T, Head R, Hoffmann P, Cosgrove L.

Proteomics. 2011 Mar;11(5):964-71. doi: 10.1002/pmic.201000429. Epub 2011 Jan 31.

PMID:
21280223
44.

Butyrate-induced apoptosis in HCT116 colorectal cancer cells includes induction of a cell stress response.

Fung KY, Brierley GV, Henderson S, Hoffmann P, McColl SR, Lockett T, Head R, Cosgrove L.

J Proteome Res. 2011 Apr 1;10(4):1860-9. doi: 10.1021/pr1011125. Epub 2011 Mar 3.

PMID:
21235278
45.
46.

Commentary: the public health consequences of an industry-influenced psychiatric taxonomy: "attenuated psychotic symptoms syndrome" as a case example.

Gopal AA, Cosgrove L, Bursztajn HJ.

Account Res. 2010 Sep;17(5):264-9. doi: 10.1080/08989621.2010.511568.

PMID:
20924809
47.

A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo.

Dransfield DT, Cohen EH, Chang Q, Sparrow LG, Bentley JD, Dolezal O, Xiao X, Peat TS, Newman J, Pilling PA, Phan T, Priebe I, Brierley GV, Kastrapeli N, Kopacz K, Martik D, Wassaf D, Rank D, Conley G, Huang Y, Adams TE, Cosgrove L.

Mol Cancer Ther. 2010 Jun;9(6):1809-19. doi: 10.1158/1535-7163.MCT-09-1134. Epub 2010 Jun 1.

48.

Structure-activity relationship of butyrate analogues on apoptosis, proliferation and histone deacetylase activity in HCT-116 human colorectal cancer cells.

Ooi CC, Good NM, Williams DB, Lewanowitsch T, Cosgrove LJ, Lockett TJ, Head RJ.

Clin Exp Pharmacol Physiol. 2010 Sep;37(9):905-11. doi: 10.1111/j.1440-1681.2010.05403.x. Epub 2010 May 24.

PMID:
20497425
49.

Silencing of the insulin receptor isoform A favors formation of type 1 insulin-like growth factor receptor (IGF-IR) homodimers and enhances ligand-induced IGF-IR activation and viability of human colon carcinoma cells.

Brierley GV, Macaulay SL, Forbes BE, Wallace JC, Cosgrove LJ, Macaulay VM.

Endocrinology. 2010 Apr;151(4):1418-27. doi: 10.1210/en.2009-1006. Epub 2010 Feb 23.

PMID:
20179263
50.

Effect of biostimulation and bioaugmentation on degradation of polyurethane buried in soil.

Cosgrove L, McGeechan PL, Handley PS, Robson GD.

Appl Environ Microbiol. 2010 Feb;76(3):810-9. doi: 10.1128/AEM.00534-09. Epub 2009 Nov 30.

Supplemental Content

Loading ...
Support Center